Quick answer: KPV is a three-residue peptide, and a 2008 study reported that cultured intestinal cells take it up through PEPT1, a proton-coupled transporter for di- and tripeptides. The data come from gut cells and models and are not settled for other tissues.
A very small peptide and a transporter that likes small peptides
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone: lysine, proline, valine. At roughly 342 daltons it is far smaller than most peptides studied in the laboratory, and that size matters for a practical reason. Cells that line the gut carry a transporter that is built to move di- and tripeptides across the membrane, and a tripeptide like KPV is a plausible fit for it.
This guide explains what the transporter is, what a 2008 study reported about KPV and that transporter in cultured cells and mice, and what a laboratory should check before designing an uptake experiment. It is background for laboratory research use only. Nothing here describes an effect or a use in people or animals. General compound background is in the KPV research overview and the what is KPV explainer.
What PEPT1 is
PEPT1, encoded by the gene SLC15A1, is a proton-coupled oligopeptide transporter. Daniel and Kottra reviewed the SLC15 family and described how these proteins use an inward proton gradient to carry short peptides across a membrane. PEPT1 is a low-affinity, high-capacity member found in the brush border of the small intestine, which is why it is central to how dietary di- and tripeptides are absorbed. A related family member, PEPT2, has higher affinity and a different tissue pattern.
Two features of the transporter explain much of the interest in it as a route for small peptides. First, it accepts a very wide range of di- and tripeptides rather than one specific sequence. Second, it is driven by a proton gradient, so conditions that change the pH on either side of the membrane change its activity. Both points matter when an experiment is designed, because a buffer with the wrong pH can look like a biological result.
Side-by-side comparison
| Question | What was reported | Source |
|---|---|---|
| What is KPV? | The C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, about 342 Da | Cutuli et al., 2000 |
| What is PEPT1? | A proton-coupled di- and tripeptide transporter (SLC15A1), abundant in the small intestine | Daniel and Kottra, 2004 |
| Is KPV taken up through PEPT1? | Reported in cultured intestinal cells expressing the transporter | Dalmasso et al., 2008 |
| What went with uptake? | Lower NF-kB and MAP kinase signaling readouts in those cells | Dalmasso et al., 2008 |
| Is there independent work? | A separate group reported KPV activity in mouse intestinal models | Kannengiesser et al., 2008 |
| Is it settled for other tissues? | No. The data are mostly from gut cells and gut models | Both 2008 papers |
What the 2008 study reported
Dalmasso and colleagues, writing in Gastroenterology, examined whether KPV is taken up through PEPT1. In cultured intestinal epithelial cells engineered to express the transporter, they reported that KPV uptake could be measured and that it was reduced by a known competing substrate of PEPT1. They also reported that KPV lowered readouts of pro-inflammatory signaling in those cells, including activity of the transcription factor NF-kB and the MAP kinase pathway, and that this lower signaling went with transporter expression.
The same group reported experiments in mouse models of intestinal inflammation, in which they described KPV-related changes in tissue readouts. This guide does not summarize the animal outcomes in detail, because they are framed as disease models and fall outside our research-use framing. What can be said safely is that the paper proposed a mechanism with several parts: the peptide enters the cell through PEPT1, and once inside it is associated with lower inflammatory signaling in that system.
A fair summary is that the paper gave data from one laboratory in defined cells and models. It did not establish that every cell type takes up KPV this way, and it did not test the compound outside the conditions described.
A second, independent line of work
Kannengiesser and colleagues published a separate 2008 study in Inflammatory Bowel Diseases that tested KPV in mouse models and reported anti-inflammatory activity in those models. It is an independent group and a different set of experiments, which is useful when weighing how well an observation holds up. It is also a reminder that the intestinal setting dominates this literature: most of what is published about KPV and PEPT1 comes from gut cells and gut models, so extrapolating to other tissues is a guess, not a finding.
For how KPV relates to the full alpha-MSH molecule and to its melanocortin receptors, see KPV vs. alpha-MSH.
Designing an uptake experiment
If you plan to test transporter dependence, several practical questions come first. Which cell system will be used, and does it express PEPT1 at a level you have confirmed? Many common cell lines express it weakly, which is why engineered lines are often used. How will you detect the peptide inside the cell? A three-residue peptide is hard to label without changing its size by a large fraction, and a bulky tag can change whether the transporter accepts it at all. Mass spectrometry of cell lysates avoids that problem but needs a validated method.
Controls carry most of the weight in this kind of study. A competing substrate, such as a well-known dipeptide, tests whether uptake is shared with the transporter. A cell line without the transporter, or with it knocked down, tests whether uptake depends on it. A temperature control (cold versus warm) separates active transport from simple binding to the cell surface. Buffer pH belongs in the notebook, because the transporter is proton driven.
Exposure conditions in cell studies belong in the laboratory's own validated protocol and are not given here.
Stability is part of the question
Short peptides can be broken down by peptidases in serum-containing medium and at the cell surface. If a peptide degrades during an experiment, a lower reading inside the cell may reflect loss of the compound outside it, not poor transport. A cautious design measures the amount of intact peptide in the medium at the start and end of the experiment, and uses serum-free or low-serum buffer for the uptake step where the cells tolerate it.
Why reagent quality matters here
With a competition-based design, a contaminant can mislead in two directions. A leftover amino acid or short fragment from synthesis could itself compete for the transporter and make uptake look lower than it is. Residual trifluoroacetic acid from purification can shift the pH of a small-volume buffer, and PEPT1 is sensitive to pH. Endotoxin, in turn, can raise baseline inflammatory signaling in epithelial cells and mask or mimic the readout. For these reasons identity, purity and endotoxin data should be fixed for each lot before the first replicate, and one lot should be used across a series where possible.
What a certificate should show
Look for the exact compound name (KPV, the tripeptide Lys-Pro-Val, is about 342 Da), a lot identifier and a test date that match the vial, plus a purity figure from HPLC and an identity result. For background on reading these documents, see understanding HPLC purity and how to read a COA.
Read the chromatogram, not just the percentage. A three-residue peptide is small and elutes early, so a deletion or a leftover synthesis fragment can sit very close to the main peak, and a crowded early baseline deserves a question to the supplier. For an uptake study, also ask whether the salt form and residual counter-ion content are stated, since they affect the pH of small-volume buffers.
V8 Peptides publishes certificates for only some products. Where one exists, it reports HPLC purity and identity, endotoxin and PCR sterility. This article describes general buyer practice and is not a statement about any particular lot. V8 lists KPV at KPV. More buyer-side guidance is in where to buy KPV, KPV purity testing and choosing a peptide supplier.
Handling and record keeping
Keep lyophilized peptide cold, dry and away from light until use, and write the opening date on the vial. Plan aliquots before opening so a vial is not handled repeatedly. In the notebook, record the exact name, sequence, lot, supplier, certificate date, buffer pH, storage conditions and opening date, so a later reader can tie any result to a defined reagent. General purity background is in KPV purity testing.
Frequently asked questions
What is PEPT1?
A proton-coupled peptide transporter encoded by SLC15A1. It carries di- and tripeptides across cell membranes and is abundant in the small intestine.
Why is KPV linked to PEPT1?
KPV is a tripeptide, which is the size PEPT1 prefers. A 2008 study reported KPV uptake through PEPT1 in cultured intestinal cells.
Does PEPT1 take up only KPV?
No. It accepts a very wide range of di- and tripeptides, which is why competition experiments are used to test dependence.
What controls help show transporter dependence?
A competing substrate, a cell line lacking the transporter, and a cold-versus-warm comparison.
Why does buffer pH matter?
PEPT1 is driven by a proton gradient, so a shift in pH changes its activity and can look like a biological effect.
Can residual trifluoroacetic acid affect an experiment?
Yes. In a small-volume buffer it can shift pH, so the certificate or supplier should state the salt form.
Is the evidence limited to the gut?
Mostly. The main reports come from intestinal cells and models, so other tissues are untested territory.
Why measure intact peptide in the medium?
Short peptides can be broken down by peptidases, which could be mistaken for poor uptake.
Does V8 sell KPV?
Yes, for laboratory research use only.
Does this article describe a use in people?
No. It summarizes published cell and animal research and analytical practice. No product is sold for human or animal consumption.
What should I record for each vial?
The exact compound name, lot identifier, certificate date, supplier, storage conditions and the date the vial was opened.
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
- Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004;447(5):610-618.
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239.